China's ADC/XDC Pipeline Fuels Global Breakthroughs
China’s growing strength in the XDC field is reflected in a surge of overseas transactions, with an increasing number of overseas companies licensing pipelines from Chinese innovators. To date, overseas XDC transactions have totaled $28 billion across 27 deals. While earlier agreements often focused on popular targets such as HER2 and Trop2, recent partnerships have begun to shift toward novel targets like CCR9, CDH6, and CDH17.
Notably, among the 22 Chinese companies with overseas ADC/XDC deals, ChemExpress has participated in over 95%—providing both technical services and the supply of intermediates.
As ADCs continue to drive global biopharma innovation, Chinese companies are earning growing international recognition for their strong R&D and integrated supply chains. At ChemExpress, we deliver world-class quality and service to help innovators expand globally and succeed on the international stage.
You may also be interested in:
·The Rise of Site-Specific ADCs: Trends and Innovations
·Empowering ADC Development with High-Quality Payload Solutions Solutions
·AACR 2025 Preview : Rising Momentum for Dual-Payload ADCs